Open AccessSurgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease
Author(s) -
Taleen A. MacArthur,
Aodhnait S. Fahy,
James W. Jakub
Publication year - 2021
Publication title -
the american surgeon/american surgeon
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 93
eISSN - 1555-9823
pISSN - 0003-1348
DOI - 10.1177/00031348211023434
Subject(s) - medicine , positron emission tomography , avidity , melanoma , oncolytic virus , radiology , disease , fluorodeoxyglucose , surgery , cancer , pathology , cancer research , antibody , immunology
Talimogene laherparepvec (TVEC) is an injectable attenuated oncolytic herpes simplex virus (HSV-1) used in the treatment of loco regionally metastatic melanoma. Lesions managed by TVEC are generally considered unresectable at time of initiation of intralesional therapy; however, a subset of patients go on to have surgical resection of loco regionally controlled disease. We sought to review our experience with surgical excision of treated lesions to offer an insight into the radiologic correlate, treatment effect, and pathological findings of intralesional TVEC therapy.